NO2579874T3 - - Google Patents

Info

Publication number
NO2579874T3
NO2579874T3 NO11728037A NO11728037A NO2579874T3 NO 2579874 T3 NO2579874 T3 NO 2579874T3 NO 11728037 A NO11728037 A NO 11728037A NO 11728037 A NO11728037 A NO 11728037A NO 2579874 T3 NO2579874 T3 NO 2579874T3
Authority
NO
Norway
Application number
NO11728037A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2579874(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2579874T3 publication Critical patent/NO2579874T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
NO11728037A 2010-06-08 2011-06-06 NO2579874T3 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1009549.5A GB2481018B (en) 2010-06-08 2010-06-08 Injectable flowable composition comprising buprenorphine
PCT/GB2011/051057 WO2011154724A2 (en) 2010-06-08 2011-06-06 Compositions

Publications (1)

Publication Number Publication Date
NO2579874T3 true NO2579874T3 (ko) 2018-06-09

Family

ID=42471306

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11728037A NO2579874T3 (ko) 2010-06-08 2011-06-06

Country Status (31)

Country Link
US (1) US8921387B2 (ko)
EP (3) EP3360538B1 (ko)
JP (2) JP5986072B2 (ko)
KR (1) KR101865689B1 (ko)
CN (1) CN103079544B (ko)
AU (1) AU2011263478B2 (ko)
BR (1) BR112012031290A2 (ko)
CA (1) CA2801676C (ko)
CL (1) CL2012003462A1 (ko)
CO (1) CO6670529A2 (ko)
CY (1) CY1120761T1 (ko)
DK (2) DK2579874T3 (ko)
ES (2) ES2939612T3 (ko)
FI (1) FI3360538T3 (ko)
GB (2) GB2481018B (ko)
HR (1) HRP20180118T1 (ko)
HU (1) HUE038275T2 (ko)
IL (2) IL223488A (ko)
LT (1) LT2579874T (ko)
MX (1) MX339209B (ko)
MY (1) MY171625A (ko)
NO (1) NO2579874T3 (ko)
NZ (1) NZ604026A (ko)
PL (1) PL2579874T3 (ko)
PT (1) PT2579874T (ko)
RS (1) RS56820B1 (ko)
RU (1) RU2607498C2 (ko)
SG (1) SG186200A1 (ko)
SI (1) SI2579874T1 (ko)
WO (1) WO2011154724A2 (ko)
ZA (1) ZA201209233B (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9566241B2 (en) 2012-02-21 2017-02-14 Auburn University Buprenorphine nanoparticle composition and methods thereof
SG11201406025UA (en) 2012-04-17 2014-11-27 Purdue Pharma Lp Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP2877155B1 (en) 2012-07-26 2020-10-28 Camurus AB Opioid formulations
EA034855B1 (ru) * 2012-07-26 2020-03-30 Камурус Аб Предшественник депо-препарата, содержащий бупренорфин, и способ лечения путем его введения
US20150320866A1 (en) * 2012-12-13 2015-11-12 Heron Therapeutics, Inc. Pharmaceutical composition comprising antiemetic compounds and polyorthoester
AU2014228313B2 (en) * 2013-03-15 2019-01-17 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
GB201404139D0 (en) * 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
WO2018048460A1 (en) 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
ES2893376T3 (es) 2014-04-21 2022-02-08 Heron Therapeutics Inc Sistemas de suministro polimérico de larga acción
DK3134070T3 (da) * 2014-04-21 2020-12-21 Heron Therapeutics Inc Sammensætninger af en polyorthoester og en organisk syre-excipiens
CA2945181C (en) 2014-04-28 2022-10-18 Orphomed, Inc. Pharmaceutically active dimers linked through phenolic hydroxyl groups
GB201419091D0 (en) * 2014-10-27 2014-12-10 Camurus Ab Formulations
AU2015341490C1 (en) 2014-11-07 2021-03-11 Indivior Uk Limited Buprenorphine dosing regimens
EA036951B1 (ru) * 2015-08-03 2021-01-19 Толмар Интернэшнл Лимитед Жидкая полимерная система доставки для длительного введения лекарственных средств
AU2016355236C1 (en) 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
AU2017325910B2 (en) * 2016-09-13 2020-08-27 Alar Pharmaceuticals Inc. Sustained-release buprenorphine formulations
WO2018229551A2 (en) 2017-06-16 2018-12-20 Indivior Uk Limited Methods to treat opioid use disorder
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
EP3743072B1 (en) 2018-01-22 2023-10-25 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
KR20210021459A (ko) * 2018-05-11 2021-02-26 에일러 파마슈티컬스 아이엔씨. 오래 지속되는 주사용 제제와 부프레노핀 유도체
US20210060316A1 (en) * 2019-08-30 2021-03-04 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
KR100374098B1 (ko) 1994-04-08 2003-06-09 아트릭스 라보라토리스, 인코포레이션 조절된방출이식편형성에적합한액체전달조성물
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) * 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
AU2003295409B2 (en) * 2002-11-06 2010-02-11 Durect Corporation Controlled release depot formulations
JP2007525429A (ja) * 2003-03-11 2007-09-06 キューエルティー ユーエスエー,インコーポレイテッド. 細胞スケジュール依存性抗癌剤のための処方
AU2005294382A1 (en) * 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8173148B2 (en) * 2004-11-10 2012-05-08 Tolmar Therapeutics, Inc. Stabilized polymeric delivery system comprising a water-insoluble polymer and an organic liquid
PT3202814T (pt) 2007-02-15 2019-11-26 Tolmar Therapeutics Inc Poli-(lactido/glicolido) de libertação imediata reduzida e métodos de produção de polímeros
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
GB2481018B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine

Also Published As

Publication number Publication date
GB2513267A (en) 2014-10-22
CL2012003462A1 (es) 2013-04-01
MX339209B (es) 2016-04-15
RS56820B1 (sr) 2018-04-30
KR20130135026A (ko) 2013-12-10
CO6670529A2 (es) 2013-05-15
AU2011263478B2 (en) 2015-01-22
JP2013533230A (ja) 2013-08-22
NZ604026A (en) 2015-01-30
FI3360538T3 (fi) 2023-03-22
EP2579874B1 (en) 2018-01-10
ES2656938T3 (es) 2018-03-01
GB2481018A (en) 2011-12-14
DK2579874T3 (da) 2018-01-29
MY171625A (en) 2019-10-21
WO2011154724A2 (en) 2011-12-15
CA2801676A1 (en) 2011-12-15
JP5986072B2 (ja) 2016-09-06
ZA201209233B (en) 2014-04-30
CN103079544A (zh) 2013-05-01
IL223488A (en) 2017-10-31
BR112012031290A2 (pt) 2016-11-01
KR101865689B1 (ko) 2018-06-08
HRP20180118T1 (hr) 2018-03-09
IL254417A0 (en) 2017-11-30
GB201009549D0 (en) 2010-07-21
WO2011154724A9 (en) 2012-08-16
EP4218720A1 (en) 2023-08-02
PT2579874T (pt) 2018-01-29
JP6251774B2 (ja) 2017-12-20
GB2513267B (en) 2015-03-18
CN103079544B (zh) 2017-06-09
CA2801676C (en) 2018-08-07
JP2016155865A (ja) 2016-09-01
LT2579874T (lt) 2018-02-12
AU2011263478A1 (en) 2013-01-10
DK3360538T3 (da) 2023-03-06
SG186200A1 (en) 2013-01-30
EP3360538B1 (en) 2023-02-15
RU2607498C2 (ru) 2017-01-10
ES2939612T3 (es) 2023-04-25
SI2579874T1 (en) 2018-03-30
MX2012014335A (es) 2013-03-05
GB2481018B (en) 2015-03-18
EP2579874A2 (en) 2013-04-17
US8921387B2 (en) 2014-12-30
WO2011154724A3 (en) 2012-07-12
EP3360538A1 (en) 2018-08-15
CY1120761T1 (el) 2019-12-11
RU2012157244A (ru) 2014-07-20
GB201413064D0 (en) 2014-09-03
US20130210853A1 (en) 2013-08-15
PL2579874T3 (pl) 2018-05-30
HUE038275T2 (hu) 2018-10-29

Similar Documents

Publication Publication Date Title
BR112013008959A2 (ko)
BR112012031500A2 (ko)
BR112012029986A2 (ko)
BR112012027808A2 (ko)
BR112012019354A2 (ko)
BR112012002126A2 (ko)
BR112012017960A2 (ko)
BR112012025482A2 (ko)
BR112013006400A2 (ko)
BR112012031826A2 (ko)
BR112012025577A2 (ko)
BR112012023249A2 (ko)
NO2579874T3 (ko)
BR112012016456A2 (ko)
BR112012018256A2 (ko)
BR112012025308A2 (ko)
BR112012024872A2 (ko)
BR112012023265A2 (ko)
BR112013010949A2 (ko)
BR112013003284A2 (ko)
BR112013002646A2 (ko)
BR112012022788A2 (ko)
BR112012023446A2 (ko)
BR112013006825A2 (ko)
BR112012016895A2 (ko)